




Marine n-3 PUFA, heart rate variability and ventricular arrhythmias in patients on
chronic dialysis
a cross-sectional study
Rantanen, Jesper M.; Schmidt, Erik B.; Riahi, Sam; Lundbye-Christensen, Søren;
Christensen, Jeppe H.
Published in:
British Journal of Nutrition





Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Rantanen, J. M., Schmidt, E. B., Riahi, S., Lundbye-Christensen, S., & Christensen, J. H. (2018). Marine n-3
PUFA, heart rate variability and ventricular arrhythmias in patients on chronic dialysis: a cross-sectional study.
British Journal of Nutrition, 120(3), 317-325. https://doi.org/10.1017/S0007114518001010
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Marine n-3 PUFA, heart rate variability and ventricular arrhythmias in patients
on chronic dialysis: a cross-sectional study
Jesper M. Rantanen1,2*, Erik B. Schmidt2,3, Sam Riahi2,3, Søren Lundbye-Christensen3,4 and
Jeppe H. Christensen1,2
1Department of Nephrology, Aalborg University Hospital, Hobrovej 18-22, 9100 Aalborg, Denmark
2Department of Clinical Medicine, Aalborg University, Sdr. Skovvej 15, 9000 Aalborg, Denmark
3AF Study Group, Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, 9100 Aalborg, Denmark
4Unit of Clinical Biostatistics, Aalborg University Hospital, Sdr. Skovvej 15, 9000 Aalborg, Denmark
(Submitted 13 November 2017 – Final revision received 16 February 2018 – Accepted 20 March 2018 – First published online 21 May 2018)
Abstract
Marine n-3 PUFA may improve autonomic dysfunction by an increase in heart rate variability (HRV) and may reduce the risk of malignant
ventricular arrhythmias. Only a few smaller studies have examined such effects in patients on chronic dialysis, who often have autonomic
dysfunction and a high risk of sudden cardiac death, which accounts for almost 30% of all deaths. This cross-sectional study investigated the
association between the plasma phospholipid content of n-3 PUFA and 24-h HRV or ventricular arrhythmias in patients on chronic dialysis.
A 48-h Holter monitoring was performed on 169 patients on in-centre dialysis (83%), home haemodialysis (10%) or peritoneal dialysis
(7%) obtaining data on arrhythmias (n 152) and 24-h HRV (n 135). The mean overall HRV (standard deviation of normal intervals (SDNN))
was low and 71% had a reduced overall HRV (SDNN< 100ms) indicating autonomic dysfunction. No significant associations between plasma
phospholipid content of total marine n-3 PUFA, EPA (22 : 5n-3) or DHA (22 : 6n-3) and time-domain or frequency-domain HRV were detected
in crude or adjusted linear regression analysis. However, a higher plasma phospholipid content of DHA was associated with a significantly
lower proportion of patients with ventricular tachycardia (higher DHA-tertile: 9% v. lower DHA-tertile: 28%, P= 0·02). In conclusion, the
content of marine n-3 PUFA in plasma phospholipids was not associated with 24-h HRV, but a higher plasma phospholipid content of DHA
was associated with a lower occurrence of ventricular tachycardia suggesting an antiarrhythmic effect of marine n-3 PUFA in patients on
chronic dialysis.
Key words: End-stage kidney disease: Heart rate variability: Ventricular arrhythmias: Autonomic dysfunction: n-3 PUFA
Patients with end-stage kidney disease (ESKD) have a very high
cardiovascular morbidity and mortality compared with the
general population. CVD remains the leading cause of death in
patients with ESKD, and sudden cardiac death (SCD) is
responsible for almost 30% of all-cause mortality in this popu-
lation(1,2). SCD is frequently a result of malignant ventricular
arrhythmias secondary to abnormalities in ventricular conduc-
tion or repolarisation(3). Cardiac autonomic dysfunction is
common in patients on chronic dialysis(4) and might be part of
the explanation for the high risk of SCD in these patients as an
imbalance in the cardiac autonomic modulation may predis-
pose to ventricular arrhythmias(5–7). Heart rate variability (HRV),
which is an analysis of beat-to-beat variation of the heart rate
(HR), is a non-invasive measure of autonomic modulation of the
heart(8). The two most used approaches for the analysis of HRV
are time-domain HRV based on simple statistical and geome-
trical measures of variability and frequency-domain HRV from
power spectral analysis. Autonomic dysfunction characterised
by excessive sympathetic activity and/or inadequate para-
sympathetic tone can be demonstrated by an attenuated
HRV(7,8), which has been shown to be a strong independent
predictor of mortality and SCD especially in patients after a
myocardial infarction(5,6,8), but also in other populations
including patients on chronic dialysis(7,9–12).
The marine n-3 PUFA, DHA (22 : 6n-3) and EPA (20 : 5n-3)
are essential fatty acids mainly derived from fatty fish, and the
intake of these fatty acids can be assessed by measurements of
content in plasma phospholipids(13). Marine n-3 PUFA have
several cardiovascular benefits and have been associated with a
reduction in cardiovascular mortality and SCD in some
studies(14–17) suggesting an antiarrhythmic effect, which also
has been seen in animal and in vitro studies(18). The possible
antiarrhythmic mechanisms are not clear, but may include a
direct effect on the myocardium by incorporation n-3 PUFA in
Abbreviations: HD, haemodialysis; HF, high frequency; HRV, heart rate variability; LF, low frequency; PD, peritoneal dialysis; SCD, sudden cardiac death;
SDNN, standard deviation of normal intervals; VT, ventricular tachycardia.
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the bilayer of the cardiomyocyte cell membrane changing the cell-
membrane fluidity or directly affecting ion channels in the cardi-
omyocytes(18,19), but also an indirect effect by changing autonomic
modulation of the heart shown by an increase in HRV(18,20).
Associations between marine n-3 PUFA, HRV and arrhythmias
have only been addressed in a few smaller studies in chronic
dialysis patients(21,22). Hence, the aim of this study was to
examine the possible associations between plasma phospholipid
content of total marine n-3 PUFA, EPA or DHA and 24-h HRV or
ventricular arrhythmias in patients on chronic dialysis.
Methods
Setting and participants
In a cross-sectional design, chronic dialysis patients from
Aalborg University Hospital and its satellite dialysis units treat-
ing all patients in the northern part of Denmark were recruited
from October 2013 to November 2015. Inclusion criteria were
treatment with haemodialysis (HD), home HD or peritoneal
dialysis (PD) for≥ 3 months and age>18 years. The only
exclusion criterion was the inability to give informed consent.
The study protocol was approved by the North Denmark
Region Committee on Health Research Ethics and all partici-
pants provided written informed consent.
Measurements
In-centre dialysis patients were examined at the dialysis unit.
Home HD patients were invited to have a standard HD session
at the dialysis unit on the day of the examination, but if they
declined (n 9) they were examined in the outpatients clinic and
received dialysis at home as usual. Patients treated with PD
followed their normal individual schedule of treatment. At the
day of the examination, the following data were obtained in
each patient: detailed medical history, anthropometric data,
blood pressure measurements (the mean of the last two of three
readings after at least 5min rest), venous blood samples, and a
48-h Holter monitoring. Regarding in-centre patients, the
Holter monitoring started just before the initiation of a dialysis
session and thus day 1 represented a dialysis day and day 2 a
non-dialysis day. Patients were encouraged to maintain normal
daily activities and abstain from strenuous exercise during the
recording.
Laboratory methods
Blood samples were drawn non-fasting for practical reasons in
the morning or the afternoon following the patients’ normal
dialysis schedule. Pre-HD blood samples were obtained from
the HD access according to the usual procedure at the
department in in-centre patients and from venepuncture in
patients examined in the outpatient clinic.
Routine haematologic and biochemical analysis were
performed according to standard routines in the central hospital
laboratory. Blood collected for plasma phospholipid fatty acid
analysis were flushed with liquid N2 to avoid oxidation and
stored at −80°C until later analysis at the Lipid Research Center,
Aalborg University Hospital. The analysis was done as
previously described(23), but in short, the fatty acid composition
in the phospholipid fraction was measured by GC (Varian 3900;
Varian) and the results expressed as weight percent (wt%) of
total fatty acids. Total marine n-3 PUFA were defined as the sum
of DHA, EPA and DPA.
Holter monitoring and heart rate variability analysis
A 48-h ECG recording was obtained in all patients using a
four-lead two-channel digital recorder (Lifecard CF; Del Mar
Reynolds Medical Limited). By using Pathfinder Digital 700
(Reynolds Medical Limited) initial editing of the recording was
done using an interactive method with visual confirmation of all
arrhythmias, premature atrial complexes, and premature ven-
tricular complexes (PVC). All non-sinus beats and artifacts were
excluded from the HRV analysis, which was done for days 1
and 2 separately. HRV analysis was only considered valid and
used in the final analysis if at least 1152min (80% of 24 h) of the
recording were analysable with sinus beats. The time-domain
HRV analyses were also done using Pathfinder Digital 700
(Reynolds Medical Limited). The following standard time-
domain HRV variables were analysed: the mean of all normal
RR-intervals (mean RR-interval); the standard deviation of all
normal RR-intervals (SDNN); the mean of the standard devia-
tion of all normal RR-intervals for all 5-min segments (SDNNi);
the standard deviation of the mean of RR-intervals in successive
5-min segments (SDANN); the square root of the mean of the
sum of the squares of differences between adjacent intervals
(rMSSD); and the total number of all RR-intervals divided by the
height of the histogram of all RR-intervals measured in a discrete
scale with bins of 7·8125 ms (triangular index). The edited files
were exported to HRV tools (Reynolds Medical Limited) to
perform power spectral analysis using Fast Fourier Transfor-
mation for the following frequency-domain measures: low fre-
quency (LF, 0·04–0·15Hz), high frequency (HF, 0·15–0·4Hz)
and LF:HF ratio. LF and HF were also given as normalised units,
which reflects the relative value of each power component in
proportion to total power minus very-low-frequency compo-
nent. The frequency-domain analyses were done in 5-min
segments with at least 90% of each segment consisting of
normal RR-intervals and then averaged on the entire 24-h
recording. The following ventricular arrhythmias were eval-
uated: the number of PVC, the occurrence of frequent PVC
(≥30/h) and occurrence of ventricular tachycardia (VT) defined
as ≥3 ventricular beats with a HR> 100 beats per min.
Statistical analysis
All statistical analyses were performed using Stata 14 (2015;
StataCorp) and a two-tailed P value of <0·05 was considered
statistically significant. Continuous variables were expressed as
means and standard deviation or medians with interquartile
ranges for normal distributed or skewed data, respectively.
Categorical variables were expressed as frequencies and per-
centages. Comparisons of HRV between days 1 and 2 were done
by paired t test or Wilcoxon’s signed-rank test depending on the
distribution for patients with available data on both days.
Comparisons of HRV between groups were made using Student’s
t test or one-way ANOVA for normally distributed data and
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Wilcoxon’s rank sum test or Kruskal–Wallis test for skewed data.
Simple linear regression was used to analyse relationships
between plasma phospholipid levels of n-3 PUFA and HRV while
multivariate linear regression was done to control for con-
founders. Using an epidemiological approach, it was a priori
decided to adjust for the following covariates: demography (age;
sex; smoking status), co-morbidity (diabetes mellitus; CHD) and
the use of medication (beta blocker; angiotensin converting
enzyme-inhibitor or angiotensin receptor blocker; statin). Sensi-
tivity analysis was done by bootstrapping with 1000 replications
to estimate standard errors and calculate estimated CI. Further-
more, the analyses were repeated excluding the most evident
outliers. Regarding ventricular arrhythmias, these were analysed
according to groups of n-3 PUFA tertiles. The χ2 test was applied
for comparison of categorical variables. Multiple logistic regres-
sion were performed to adjust for confounding, but due to a low
event count adjustments were only done for age, sex and CHD to
prevent overfitting of the model.
Results
Patient characteristics
A total of 169 patients were enrolled (Fig. 1). Baseline char-
acteristics for the total population and patients with a least 1 d
recording analysed for HRV (n 135) are listed in Table 1. The
treatment modalities were in-centre dialysis (83%), home HD
(10%) and PD (7%). The causes of ESKD were diabetes mellitus
(28%) glomerulonephritis (18%); obstructive nephropathy,
reflux or chronic pyelonephritis (13%); polycystic kidney dis-
ease (10%); hypertension and ischaemic nephropathy (9%) or
other known and unknown causes (22%).
Heart rate variability on days 1 and 2
HRV analysis was possible in 129 and 122 patients on days 1
and 2, respectively. We only obtained HRV on both days in
116 patients (Table 2). The patients had a low overall 24-h HRV
and assessed by the highest measured SDNN on days 1 or 2,
29% had a normal HRV (SDNN> 100ms), 61% had a moder-
ately reduced HRV (SDNN 50–100ms) and 10% had a severely
reduced HRV (SDNN< 50ms)(8). The mean RR-interval and the
SDNNi were higher on day 1 compared with days 2, but there
were no other statistically significant differences between the
2 d concerning other time-domain indices. Regarding
frequency-domain HRV, we observed a significantly higher LF,
normalised LF and LF:HF ratio and a lower normalised HF on
day 1 compared with day 2. To clarify the effect of the dialysis
session on HRV a subgroup analysis was done including
patients treated with in-centre dialysis and only having HD on
day 1 (n 92). This analysis showed similar results (data not
shown). CHD and diabetes mellitus were both associated with a
lower SDNN, whereas no differences were seen between men
and women or between dialysis modalities (Fig. 2).
n-3 PUFA and heart rate variability
No significant associations were observed between the contents
of DHA or EPA in plasma phospholipids and time-domain or
frequency-domain HRV in the crude or adjusted multiple linear
regression analysis (Fig. 3 and Table 3). Analyses were also
done for total marine n-3 PUFA with the similar results of no
association with HRV (data not shown). Sensitivity analysis
using bootstrap methods showed similar results (data not
shown). A few patients had very high levels of the exposure
variable (n-3 PUFA) and repeating the analyses excluding these
outliers did not change the results. For the main overall 24-h
HRV parameter SDNN mostly used for risk stratification for
SCD, we performed additional subanalyses with data stratified
by modality, sex, the presence of diabetes mellitus and pre-
sence of CHD. These subanalyses also showed no significant
associations between DHA, EPA or total marine n-3 PUFA and
SDNN (data not shown).
n-3 PUFA and ventricular arrhythmias
Arrhythmias analyses on recordings with >80% of the 24-h was
obtainable in 152 patients. Patients were grouped according to
Excluded (n 83)
Not meeting eligibility criteria (n 26)
Declined to participate (n 48)
Intercurrent disease (n 9)
Included in the study (n 169)
HRV day 1 (n 129)
Excluded (n 6):
< 80 % recording analysed on day 1 (n 5)
Atrial fibrillation only day 1(n 1)
HRV day 2 (n 122)
Excluded (n 13):
< 80 % recording analysed on day 2 (n 13)
HRV (n 135) 
Excluded from analysis:
Atrial fibrillation (n 19)
Multifocal supraventricular rhythm (n 1)
Frequent pace rhythm (n 2)
Frequent nodal rhythm (n 1)
Frequent premature atrial complexes not possible to edit 
correctly (n 2)
< 80 % recording analysed for HRV on both days (n 9)
Assessed for eligibility (n 252)
Fig. 1. Study flow chart. HRV, heart rate variability.
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marine n-3 PUFA tertiles to assess the associations of n-3 PUFA
and ventricular arrhythmias (Table 4). There were no significant
associations with ventricular arrhythmias regarding total marine
n-3 PUFA or EPA. However, the content of DHA in plasma
phospholipids was associated with a significantly lower pro-
portion of patients with non-sustained VT (Fig. 4). Comparing
the lower and upper tertiles of DHA the odds for the presence
of VT was 3·8-fold (P= 0·02) and 6·9-fold (P= 0·002) higher in
the lowest tertile of DHA in crude and adjusted logistic
regression analysis, respectively.
Discussion
The present study is to our knowledge the largest study
investigating the associations between n-3 PUFA and HRV in
patients on chronic dialysis. This is also the first study to address
associations between ventricular arrhythmias documented by
Holter monitoring with plasma content of n-3 PUFA in patients
on chronic dialysis. We were unable to demonstrate any asso-
ciations between n-3 PUFA levels in plasma phospholipids and
HRV. However, higher plasma phospholipid levels of DHA
were associated with a lower proportion of patients with non-
sustained VT.
The patients in our study had an attenuated 24-h overall
HRV (SDNN) at a similar or even lower level than most earlier
studies in patients on chronic dialysis(4,21,24). Furthermore,
10% had a severely reduced overall HRV (SDNN<50ms) which
may be explained by a population with a high level of
co-morbidities including CHD and diabetes mellitus, which
often lead to a more pronounced reduction in HRV(4,8,9), which
we also observed in our study. Moreover, we did not observe
any difference of overall HRV (SDNN and triangular index)
between day 1 (the dialysis day for in-centre patients) and day 2
(without dialysis), but we did see a significantly higher LF,
normalised LF and LF:HF ratio and a lower normalised HF on
day 1 compared with day 2. This may be interpreted as a
change in the sympatho-vagal balance toward a decrease in
vagal modulation and/or an increase in sympathetic modulation
on the dialysis day compared with the non-dialysis day, which
may be explained by the cardiovascular stress caused by
ultrafiltration-induced intravascular hypovolemia on the
dialysis day(25).
Evidence of associations between intake of fish or n-3 PUFA
and the cardiovascular outcome is sparse in patients on chronic
dialysis. In a retrospective study, Kutner et al.(26) reported that
fish intake was associated with reduced mortality in 216 inci-
dent PD and HD patients. In some epidemiologic studies
DHA(27,28), EPA(29) and the Omega-3 index (EPA +DHA in
erythrocytes)(30) have also been associated with significantly
lower mortality in HD patients. In a case–control study(31) of
100 HD patients who died of SCD and 300 patients, who sur-
vived the 1st year of dialysis, a striking inverse relationship
between serum phospholipid total marine n-3 PUFA and the
odds of SCD was observed. In contrast to this, Huang et al.(32)
reported that plasma levels of linoleic acid, but not of DHA, EPA
or DPA was associated with lower mortality in 222 incident PD
and HD patients before kidney transplantation. Only two ran-
domized controlled trials have assessed n-3 PUFA supple-
mentation on cardiovascular events in patients on chronic
dialysis. A study from our institution(33) showed no effect of
supplementation of 1·7 g marine n-3 PUFA for 2 years on a
composite primary endpoint of total cardiovascular events and
Table 1. Baseline characteristics for all patients and patients with heart
rate variability (HRV) analysis
(Percentages and numbers; mean values and standard deviations; med-





n % n %
Sex
Male 110 65·1 86 63·7
Female 59 34·9 49 36·3
Ethnicity
Caucasian 165 97·6 132 97·8
Asian 4 2·4 3 2·2
Current smoking 34 20·1 29 21·5
Co-morbidity
Hypertension 153 90·5 124 91·9
Diabetes mellitus, type 1 21 12·4 21 15·6
Diabetes mellitus, type 2 39 23·1 29 21·5
CHD 52 30·8 37 27·4
Ischaemic stroke 35 20·7 26 19·3
Haemorrhagic stroke 10 5·9 8 5·9
Peripheral artery disease 32 18·9 20 14·8
Medication
Beta blocker 107 63·3 83 61·5
ACE inhibitor 32 18·9 26 19·3
ARB 45 26·6 39 28·9
Statin 65 38·5 54 40·0
Mean SD Mean SD
Age (years) 62·3 14·1 59·9 14·2
Dialysis vintage (years)
Median 1·80 1·70
IQR 0·62, 5·67 0·59, 5·46
Weight (kg)* 78·8 18·7 78·6 19·0
BMI (kg/m²) 27·1 6·2 27·0 6·1
Blood pressure (mmHg)†
Systolic 143·3 25·9 145·3 24·3
Diastolic 73·0 13·1 75·0 12·5
Blood




IQR 1·9, 9·6 1·6, 9·0
Albumin (g/l) 32·2 3·9 32·3 3·9
High-sensitive troponin T (ng/l)
Median 57 53
IQR 33, 98 32, 94
Total cholesterol (mmol/l) 4·3 1·4 4·4 1·4
HDL-cholesterol (mmol/l) 1·19 0·40 1·19 0·41
LDL-cholesterol (mmol/l) 2·35 1·16 2·38 1·20
TAG (mmol/l)
Median 1·5 1·5
IQR 1·0, 2·2 1·0, 2·3
Plasma phospholipid (weight %)
20 : 5n-3 (EPA) 1·69 1·18 1·69 1·24
22 : 6n-3 (DHA) 4·17 1·24 4·15 1·25
Total n-3 PUFA (EPA+DHA+DPA) 6·97 2·25 6·95 2·31
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.
* Weight: measured after ultrafiltration in in-centre patients.
† Measurement before haemodialysis on in-centre patients, and at a random time in
patients examined in the outpatient clinic.








bridge.org/core . Aalborg U
niversity Library , on 05 Jul 2019 at 08:09:23 , subject to the Cam
bridge Core term






death in 206 HD patients with known CHD, but a significant
reduction in the risk of myocardial infarction as a secondary
outcome was observed. In another study on arterio-venous-graft
patency Lok et al.(34) demonstrated (as a secondary outcome) an
improved cardiovascular event-free survival in patients treated
with 2·4g n-3 PUFA compared with placebo for 1 year.
Table 2. Heart rate variability on 2 consecutive days in patients on chronic dialysis
(Mean values and standard deviation; medians and interquartile ranges (IQR))
Day 1* Day 2*
All (n 129) Paired (n 116) All (n 122) Paired (n 116)
Mean SD Mean SD Mean SD Mean SD P†
Time-domain
Mean RR (ms) 819·7 120·3 818·1 121·0 803·2 115·0 803·0 115·8 <0·001
SDNN (ms) 83·8 33·3 83·6 32·8 81·8 34·0 83·1 34·3 0·76
SDNNi (ms)
Median 26 27 24 25 0·02
IQR 19, 36 19, 36 18, 34 18, 36
SDANN (ms)
Median 70 71 69 70 0·96
IQR 55, 92 56, 93 52, 88 54, 90
rMSSD(ms)
Median 13 12 12 12 0·13
IQR 9, 17 9, 17 9, 16 9, 16
Triangular Index
Median 21 21 20 21 0·62
IQR 16, 27 16, 27 15, 27 15, 27
Frequency-domain
LF (ms²)
Median 106 115 87 93 0·007
IQR 40, 251 42, 256 30, 220 33, 225
LF (nu) 61·1 19·7 63·1 18·5 60·0 19·7 60·8 19·1 0·001
HF (ms²)
Median 41 40 36 37 0·63
IQR 18, 74 18, 70 20, 65 21, 72
HF (nu) 28·3 13·7 27·2 12·6 29·3 14·6 28·9 14·3 0·01
LF:HF ratio
Median 2·47 2·59 2·27 2·29 0·02
IQR 1·38, 4·15 1·49, 4·29 1·45, 3·93 1·45, 3·97
Mean RR, 24-h mean value of RR-intervals; SDNN, 24-h standard deviation of normal intervals; SDANN, standard deviation of the mean of RR-intervals in
successive 5-min segments; SDNNi, mean of the standard deviation of all normal RR-intervals for all 5-min segments; rMSSD, square root of the mean
of the sum of the squares of differences between adjacent intervals; LF, low frequency; nu, normalised units; HF, high frequency.
* Day 1 was a dialysis day and day 2 a non-dialysis day in patients on in-centre dialysis.
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Fig. 2. Mean 24-h standard deviation of normal intervals (SDNN) stratified by DM, CHD, sex or dialysis modality. Significantly lower SDNN was observed with the
presence of DM (* P= 0·0001; † P= 0·005) or CHD (‡ P= 0·01 and § P=0·02). Comparisons between groups were made for each day. HD, haemodialysis; PD,
peritoneal dialysis; , day 1; , day 2.
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A part of the suggested protective effect of n-3 PUFA on SCD
may be improvement of autonomic modulation of the heart
expressed as an increase in HRV(20). This has been seen in
some studies in high-risk populations with CHD(35–38), but
negative findings have also been reported(39–42). Only two small
studies have examined the effects of marine n-3 PUFA on HRV
in patients on chronic dialysis(21,22). In a randomised controlled
design(21), twenty-nine HD and PD patients were allocated to
5·2 g n-3 PUFA or placebo for 12 weeks. Only seventeen
completed the study that showed no effect between treatment
groups, but after supplementation a positive correlation
between granulocyte levels of n-3 PUFA and 24-h SDNN was
noted. In another trial(22), forty-three HD patients with CHD
were allocated to 1·7 g n-3 PUFA daily for 3 months. Only thirty
patients were included in the final analysis showing no effects
on 24-h time-domain HRV. In the present study, no association
was found between plasma phospholipid content of marine n-3
PUFA and HRV in patients on chronic dialysis. The reason for
this could be a truly absent effect on HRV in this population.
These patients have a very high level of co-morbidities and a
high degree of autonomic dysfunction, which might result in
inability of marine n-3 PUFA to exert a beneficial effect on HRV,
which also has been suggested in diabetics with overt auto-
nomic neuropathy(43). The use of multiple medication including
beta blockers and statins may also have impeded the possibility
to show associations between the plasma phospholipid content
of n-3 PUFA and HRV(40). ESKD has been associated with a low
intake of marine n-3 PUFA especially in American cohorts(44,45).
In our study the patients had a higher mean plasma phospho-
lipid level of marine n-3 PUFA than seen in most of these
studies indicating a higher n-3 PUFA intake. However, the
marine n-3 PUFA levels could still be too low to affect auto-
nomic function in this population explaining the negative
findings regarding HRV.
The present study is the first to demonstrate that a higher
plasma phospholipid content of DHA is associated with a lower
presence of non-sustained VT in patients on chronic dialysis.
Similar findings with a protective effect of marine n-3 PUFA on
malignant ventricular arrhythmias have been observed in
patients with idiopathic cardiomyopathy(46) and CHD(42).
Chance as a reason for the detected association must be con-
sidered due to the cross-sectional design and several endpoints.
In line with this, no protective effect of marine n-3 PUFA on
malignant ventricular arrhythmias was seen in studies on high-
risk patients with implantable cardioverter defibrillators(47–50).
The finding of a potential protective effect on VT of the plasma
phospholipid content of DHA and no observed effect on HRV
suggests that an antiarrhythmic effect in this high-risk popula-
tion mainly is due to a direct effect on the heart and not by
improvement of autonomic control. In agreement with our
results, it has been suggested that DHA has more potent anti-
arrhythmic effects than EPA(17,18). This is also plausible as the
myocardial content of DHA is higher than that of EPA(18).
This study had several strengths. The use of biological mea-
sures of plasma phospholipid content of n-3 PUFA reduced the
risk of information bias. The use of 24-h HRV as an endpoint has
the advantage that it is an objective measure with high reprodu-
cibility(8). The study population was unselected increasing
external validity. Several limitations however also merit con-
sideration. The cross-sectional design makes it impossible to
make any conclusions on cause-effect relationships. HRV was
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Fig. 3. Associations between DHA or EPA and overall heart rate variability (HRV) (24-h standard deviation of normal intervals (SDNN)) in patients on chronic dialysis.
The first column shows results from day 1 and the second column shows results from day 2. The lines represent the regression lines of the simple linear regression
analyses. There was no significant associations between DHA, EPA and SDNN. wt%, weight percent.
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Table 4. Associations between plasma phospholipid marine n-3 PUFA levels and ventricular arrhythmias on 48-h Holter monitoring
(Medians and interquartile ranges (IQR); numbers and percentages)
1st n-3 PUFA tertile 2nd n-3 PUFA tertile 3rd n-3 PUFA tertile
Median IQR Median IQR Median IQR P*
Number of PVC
DHA tertiles 57 7, 716 121 7, 870 25 4, 237 0·26
EPA tertiles 25 5, 345 28 7, 862 60 7, 327 0·78
Total n-3 PUFA tertiles 28 6, 322 138 8, 1038 42 5, 237 0·27
n % n % n %
Frequent PVC†
DHA tertiles 9 18 10 21 5 9 0·24
EPA tertiles 5 10 12 24 7 13 0·17
Total n-3 PUFA tertiles 6 12 12 23 6 12 0·21
Ventricular tachycardia‡
DHA tertiles 14 28 11 23 5 9 0·04
EPA tertiles 9 19 12 24 9 17 0·69
Total n-3 PUFA tertiles 11 22 13 25 6 12 0·20
PVC, premature ventricular complexes.
* χ2 Test or Kruskal–Wallis test.
† >30 PVCs/h.
‡ ≥3 ventricular beats with heart rate >100 beats per min.
Table 3. Regression coefficients from simple and multivariate linear regression analyses of associations between heart rate varia-
bility (HRV) and DHA or EPA content in plasma phospholipids
(Regression coefficients (β) and P values)
DHA EPA
Crude β Adjusted β* Crude β Adjusted β*
Mean P Mean P Mean P Mean P
Time-domain
Day 1
Mean RR (ms) −0·72 0·93 −11·4 0·16 −1·94 0·82 −5·56 0·48
SDNN (ms) 1·03 0·66 0·26 0·91 −3·30 0·16 −3·35 0·14
SDANN (ms) 1·31 0·55 0·67 0·76 −2·47 0·26 −2·80 0·19
SDNNi (ms) −0·37 0·70 −0·70 0·47 −1·83 0·06 −1·42 0·13
rMSSD (ms) 0·14 0·84 −0·65 0·65 −0·75 0·28 −1·06 0·13
Triangular Index 0·14 0·83 0·03 0·97 −1·13 0·09 −1·05 0·11
Day 2
Mean RR (ms) −3·15 0·71 −8·2 0·33 −3·68 0·65 −3·42 0·67
SDNN (ms) 2·05 0·40 1·75 0·51 −1·78 0·46 −1·04 0·68
SDANN (ms) 2·39 0·31 2·08 0·42 −1·17 0·61 −0·62 0·80
SDNNi (ms) −0·36 0·71 −0·42 0·67 −1·67 0·08 −1·08 0·25
rMSSD (ms) 0·24 0·66 −0·44 0·46 −0·56 0·29 −0·76 0·17
Triangular Index 0·46 0·50 0·48 0·52 −0·62 0·36 −0·34 0·62
Frequency-domain
Day 1
LF (ms²) −4·82 0·77 1·42 0·94 −22·1 0·19 −10·6 0·53
HF (ms²) −0·23 0·98 −0·19 0·98 −12·5 0·12 −10·4 0·21
LF (nu) 0·47 0·74 0·42 0·76 −1·64 0·24 −0·68 0·61
HF (nu) −0·64 0·51 −0·64 0·51 0·62 0·52 0·26 0·79
LF:HF ratio 0·12 0·55 0·28 0·17 0·08 0·66 0·29 0·13
Day 2
LF(ms²) −7·36 0·67 2·09 0·95 −15·6 0·36 −2·78 0·87
HF (ms²) 0·42 0·96 0·55 0·94 −9·21 0·21 −7·74 0·32
LF (nu) 0·20 0·89 1·01 0·49 −1·81 0·19 −0·40 0·77
HF (nu) −0·23 0·83 −0·38 0·74 1·15 0·27 0·63 0·55
LF:HF ratio 0·08 0·69 0·30 0·17 0·02 0·91 0·24 0·25
Mean RR, 24-h mean value of RR-intervals; SDNN, 24-h standard deviation of normal intervals; SDANN, standard deviation of the mean of RR-intervals in
successive 5-min segments; SDNNi, mean of the standard deviation of all normal RR-intervals for all 5-min segments; rMSSD, square root of the mean
of the sum of the squares of differences between adjacent intervals; LF, low frequency; nu, normalised units; HF, high frequency.
* Adjustments were done for the following covariates: demography (age; sex; smoking status), co-morbidity (diabetes mellitus; CHD) and use of
medication (beta blocker; angiotensin-converting enzyme-inhibitor or angiotensin receptor blocker; statin).
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characteristics and plasma phospholipid content of marine n-3
PUFA were comparable suggesting this sample was representa-
tive of the entire population. Furthermore, the relatively small
sample size increased the risk of failure to detect real associations
(type II error). We adjusted for a number of potential con-
founders, but the heterogeneous nature of chronic dialysis
patients increased the risk of residual confounding.
In conclusion, our study did not demonstrate any association
between the plasma phospholipid content of marine n-3 PUFA
and HRV in patients on chronic dialysis. A higher plasma phos-
pholipid content of DHA was however associated with a lower
proportion of patients experiencing non-sustained VT suggesting
a direct antiarrhythmic effect in this high-risk population. Whether
supplementation of n-3 PUFA has positive effects on autonomic
control and ventricular arrhythmias in this patient population
remains to be seen and needs to be clarified through adequately
powered randomised controlled trials.
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